HDAC Inhibition Blunts Ischemia/Reperfusion Injury by Inducing Cardiomyocyte Autophagy

BACKGROUND: Reperfusion accounts for a substantial fraction of the myocardial injury occurring with ischemic heart disease. Yet, no standard therapies are available targeting reperfusion injury. Here, we tested the hypothesis that SAHA, a histone deacetylase (HDAC) inhibitor FDA-approved for cancer...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Xie, Min, Kong, Yongli, Tan, Wei, May, Herman, Battiprolu, Pavan K., Pedrozo, Zully, Wang, Zhao, Morales, Cyndi, Luo, Xiang, Cho, Geoffrey, Jiang, Nan, Jessen, Michael E., Warner, John J., Lavandero, Sergio, Gillette, Thomas G., Turer, Aslan T., Hill, Joseph A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2014
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3984913/
https://ncbi.nlm.nih.gov/pubmed/24396039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.113.002416
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares